| 1 | Introducing Metal–Organic Frameworks to Melt Electrowriting: Multifunctional Scaffolds with Controlled Microarchitecture for Tissue Engineering Applications | 17.0 | 24 | Citations (PDF) |
| 2 | Potent Anticancer Activity of a Dinuclear Gold(I) bis‐<i>N</i>‐Heterocyclic Imine Complex Related to Thioredoxin Reductase Inhibition <i>in Vitro</i> | 2.7 | 7 | Citations (PDF) |
| 3 | Metals in Cancer Research: Beyond Platinum Metallodrugs | 9.2 | 92 | Citations (PDF) |
| 4 | A graft-to strategy of poly(vinylphosphonates) on dopazide-coated gold nanoparticles using <i>in situ</i> catalyst activation | 4.4 | 3 | Citations (PDF) |
| 5 | (SiFA)SeFe: A Hydrophilic Silicon-Based Fluoride Acceptor Enabling Versatile Peptidic Radiohybrid Tracers | 5.6 | 7 | Citations (PDF) |
| 6 | Assembling a new generation of radiopharmaceuticals with supramolecular theranostics | 46.7 | 21 | Citations (PDF) |
| 7 | PET Imaging of Self‐Assembled <sup>18</sup>F‐Labelled Pd<sub>2</sub>L<sub>4</sub> Metallacages for Anticancer Drug Delivery | 3.4 | 19 | Citations (PDF) |
| 8 | Bioinorganic supramolecular coordination complexes and their biomedical applications | 2.7 | 35 | Citations (PDF) |
| 9 | Gold Complexes in Anticancer Therapy: From New Design Principles to Particle‐Based Delivery Systems | 14.4 | 152 | Citations (PDF) |
| 10 | Elucidating the Multimodal Anticancer Mechanism of an Organometallic Terpyridine Platinum(II) N-Heterocyclic Carbene Complex against Triple-Negative Breast Cancer In Vitro and In Vivo | 5.6 | 24 | Citations (PDF) |
| 11 | Gold Complexes in Anticancer Therapy: From New Design Principles to Particle‐Based Delivery Systems | 1.4 | 12 | Citations (PDF) |
| 12 | Organometallic Pillarplexes That Bind DNA 4-Way Holliday Junctions and Forks | 15.0 | 23 | Citations (PDF) |
| 13 | Electrochemical Detection of Drugs via a Supramolecular Cucurbit[7]uril-Based Indicator Displacement Assay | 8.5 | 16 | Citations (PDF) |
| 14 | Exploring the Anticancer Activity of Tamoxifen-Based Metal Complexes Targeting Mitochondria | 5.6 | 35 | Citations (PDF) |
| 15 | Synthesis of <sup>177</sup>Lu-Labeled, Somatostatin-2 Receptor-Targeted Metalla-Assemblies: Challenges in the Design of Supramolecular Radiotherapeutics | 4.6 | 8 | Citations (PDF) |
| 16 | Application of Machine Learning Algorithms to Metadynamics for the Elucidation of the Binding Modes and Free Energy Landscape of Drug/Target Interactions: a Case Study | 3.4 | 10 | Citations (PDF) |
| 17 | Beyond Metal-Arenes: Monocarbonyl Ruthenium(II) Catalysts for Transfer Hydrogenation Reactions in Water and in Cells | 12.4 | 16 | Citations (PDF) |
| 18 | Seeing the invisible: Preparative strategies to visualise elusive molecules using mass spectrometry imaging | 11.2 | 6 | Citations (PDF) |
| 19 | Bio-based and bio-inspired adhesives from animals and plants for biomedical applications | 7.1 | 67 | Citations (PDF) |
| 20 | Aquaglyceroporin Modulators as Emergent Pharmacological Molecules for Human Diseases | 3.6 | 20 | Citations (PDF) |
| 21 | Competitive profiling of ligandable cysteines in <i>Staphylococcus aureus</i> with an organogold compound | 3.4 | 21 | Citations (PDF) |
| 22 | Indenyl and Allyl Palladate Complexes Bearing<i>N</i>‐Heterocyclic Carbene Ligands: an Easily Accessible Class of New Anticancer Drug Candidates | 1.8 | 35 | Citations (PDF) |
| 23 | Highly-fluorescent BODIPY-functionalised metallacages as drug delivery systems: synthesis, characterisation and cellular accumulation studies | 3.0 | 16 | Citations (PDF) |
| 24 | Cyclodextrin metal–organic frameworks and derivatives: recent developments and applications | 37.8 | 144 | Citations (PDF) |
| 25 | Bottom‐up Synthesis of Water‐Soluble Gold Nanoparticles Stabilized by N‐Heterocyclic Carbenes: From Structural Characterization to Applications | 3.4 | 28 | Citations (PDF) |
| 26 | Optimization of the Pharmacokinetic Profile of [99mTc]Tc-N4-Bombesin Derivatives by Modification of the Pharmacophoric Gln-Trp Sequence | 4.4 | 6 | Citations (PDF) |
| 27 | “Dynamical Docking” of Cyclic Dinuclear Au(I) Bis-N-heterocyclic Complexes Facilitates Their Binding to G-Quadruplexes | 4.6 | 15 | Citations (PDF) |
| 28 | Identifying and validating the presence of Guanine-Quadruplexes (G4) within the blood fluke parasite Schistosoma mansoni | 3.1 | 7 | Citations (PDF) |
| 29 | N-Heterocyclic carbenes as “smart” gold nanoparticle stabilizers: State-of-the art and perspectives for biomedical applications | 2.1 | 34 | Citations (PDF) |
| 30 | Therapeutic potential of a copper complex loaded in pH-sensitive long circulating liposomes for colon cancer management | 4.8 | 49 | Citations (PDF) |
| 31 | Interfering with Metabolic Profile of Triple‐Negative Breast Cancers Using Rationally Designed Metformin Prodrugs | 1.4 | 3 | Citations (PDF) |
| 32 | The Beauty of Gold: Knowledge of Mechanisms Leads to Different Applications of Organogold Compounds in Medicine and Catalysis | 1.1 | 14 | Citations (PDF) |
| 33 | Interfering with Metabolic Profile of Triple‐Negative Breast Cancers Using Rationally Designed Metformin Prodrugs | 14.4 | 64 | Citations (PDF) |
| 34 | Host–Guest Interactions in a Metal–Organic Framework Isoreticular Series for Molecular Photocatalytic CO<sub>2</sub> Reduction | 14.4 | 119 | Citations (PDF) |
| 35 | An Organogold Compound as Potential Antimicrobial Agent against Drug‐Resistant Bacteria: Initial Mechanistic Insights | 3.1 | 36 | Citations (PDF) |
| 36 | Investigation of Solvatomorphism and Its Photophysical Implications for Archetypal Trinuclear Au3(1-Methylimidazolate)3 | 4.3 | 1 | Citations (PDF) |
| 37 | C−C Cross‐Couplings from a Cyclometalated Au(III) CN Complex: Mechanistic Insights and Synthetic Developments | 3.4 | 11 | Citations (PDF) |
| 38 | Mechanisms of irreversible aquaporin-10 inhibition by organogold compounds studied by combined biophysical methods and atomistic simulations | 2.6 | 8 | Citations (PDF) |
| 39 | Bioconjugate Supramolecular Pd<sup>2+</sup> Metallacages Penetrate the Blood Brain Barrier <i>In Vitro</i> and <i>In Vivo</i> | 3.9 | 47 | Citations (PDF) |
| 40 | Comparative biological evaluation and G-quadruplex interaction studies of two new families of organometallic gold(I) complexes featuring N-heterocyclic carbene and alkynyl ligands | 3.0 | 49 | Citations (PDF) |
| 41 | Exploring the Reactivity and Biological Effects of Heteroleptic N‐Heterocyclic Carbene Gold(I)‐Alkynyl Complexes | 1.8 | 42 | Citations (PDF) |
| 42 | Human red blood cell uptake and sequestration of arsenite and selenite: Evidence of seleno-bis(S-glutathionyl) arsinium ion formation in human cells | 5.2 | 10 | Citations (PDF) |
| 43 | Insights into the Selectivity Mechanisms of Grapevine NIP Aquaporins | 4.5 | 13 | Citations (PDF) |
| 44 | Comparing the Antileishmanial Activity of Gold(I) and Gold(III) Compounds in <i>L. amazonensis</i> and <i>L. braziliensis in Vitro</i> | 3.1 | 38 | Citations (PDF) |
| 45 | An Organometallic Gold(I) Bis‐N‐Heterocyclic Carbene Complex with Multimodal Activity in Ovarian Cancer Cells | 3.4 | 63 | Citations (PDF) |
| 46 | Exploring the Chemoselectivity towards Cysteine Arylation by Cyclometallated Au<sup>III</sup> Compounds: New Mechanistic Insights | 2.6 | 31 | Citations (PDF) |
| 47 | Gold compounds for catalysis and metal-mediated transformations in biological systems | 5.9 | 59 | Citations (PDF) |
| 48 | Glutathione-responsive cyclodextrin-nanosponges as drug delivery systems for doxorubicin: Evaluation of toxicity and transport mechanisms in the liver | 2.7 | 45 | Citations (PDF) |
| 49 | Carbon–Phosphorus Coupling from C^N Cyclometalated Au<sup>III</sup> Complexes | 3.4 | 24 | Citations (PDF) |
| 50 | Design Strategies and Medicinal Applications of Metal-Peptidic Bioconjugates | 3.9 | 52 | Citations (PDF) |
| 51 | Targeted imaging of integrins in cancer tissues using photocleavable Ru(<scp>ii</scp>) polypyridine complexes as mass-tags | 3.4 | 18 | Citations (PDF) |
| 52 | Aquaporin-3 is involved in NLRP3-inflammasome activation contributing to the setting of inflammatory response | 5.6 | 46 | Citations (PDF) |
| 53 | Aquaporin-driven hydrogen peroxide transport: a case of molecular mimicry? | 3.3 | 26 | Citations (PDF) |
| 54 | Highly luminescent metallacages featuring bispyridyl ligands functionalised with BODIPY for imaging in cancer cells | 3.0 | 31 | Citations (PDF) |
| 55 | <i>In My Element</i>: Gold | 3.4 | 1 | Citations (PDF) |
| 56 | The antifibrotic potential of a sustained release formulation of a PDGFβ-receptor targeted rho kinase inhibitor | 11.1 | 20 | Citations (PDF) |
| 57 | Recent Developments of Supramolecular Metal-based Structures for Applications in Cancer Therapy and Imaging | 11.5 | 172 | Citations (PDF) |
| 58 | Unveiling the Mechanisms of Aquaglyceroporin‐3 Water and Glycerol Permeation by Metadynamics | 3.4 | 21 | Citations (PDF) |
| 59 | Sperm selection with density gradient centrifugation and swim up: effect on DNA fragmentation in viable spermatozoa | 3.5 | 115 | Citations (PDF) |
| 60 | Cyclometalated Au<sup>III</sup> Complexes for Cysteine Arylation in Zinc Finger Protein Domains: towards Controlled Reductive Elimination | 3.4 | 66 | Citations (PDF) |
| 61 | Exo-Functionalized Metallacages as Host-Guest Systems for the Anticancer Drug Cisplatin | 3.6 | 22 | Citations (PDF) |
| 62 | Copper Complex Nanoformulations Featuring Highly Promising Therapeutic Potential in Murine Melanoma Models | 3.1 | 50 | Citations (PDF) |
| 63 | Mediterranean, but not lacto-ovo-vegetarian, diet positively influence circulating progenitor cells for cardiovascular prevention: The CARDIVEG study | 3.4 | 8 | Citations (PDF) |
| 64 | Ex vivo toxicological evaluation of experimental anticancer gold(i) complexes with lansoprazole-type ligands | 2.2 | 11 | Citations (PDF) |
| 65 | Effects of a 3-month dietary intervention with a lacto-ovo-vegetarian diet on vitamin B12 levels in a group of omnivores: results from the CARDIVEG (Cardiovascular Prevention with Vegetarian Diet) study | 2.5 | 2 | Citations (PDF) |
| 66 | Imaging of protein distribution in tissues using mass spectrometry: An interdisciplinary challenge | 11.2 | 49 | Citations (PDF) |
| 67 | Inhibition Mechanism of Urease by Au(III) Compounds Unveiled by X-ray Diffraction Analysis | 3.4 | 35 | Citations (PDF) |
| 68 | Insights into the Mechanisms of Aquaporin-3 Inhibition by Gold(III) Complexes: the Importance of Non-Coordinative Adduct Formation | 4.6 | 36 | Citations (PDF) |
| 69 | Anticancer Gold(III) Peptidomimetics: From Synthesis to in vitro and ex vivo Biological Evaluations | 3.1 | 28 | Citations (PDF) |
| 70 | Selective targeting of PARP-1 zinc finger recognition domains with Au(<scp>iii</scp>) organometallics | 3.4 | 51 | Citations (PDF) |
| 71 | Gold(III) Pyridine-Benzimidazole Complexes as Aquaglyceroporin Inhibitors and Antiproliferative Agents | 2.8 | 15 | Citations (PDF) |
| 72 | Molecular Basis of Aquaporin-7 Permeability Regulation by pH | 4.8 | 36 | Citations (PDF) |
| 73 | New Variations on the Theme of Gold(III) C<sup>∧</sup>N<sup>∧</sup>N Cyclometalated Complexes as Anticancer Agents: Synthesis and Biological Characterization | 4.6 | 35 | Citations (PDF) |
| 74 | Relevance of Copper and Organic Cation Transporters in the Activity and Transport Mechanisms of an Anticancer Cyclometallated Gold(III) Compound in Comparison to Cisplatin | 3.6 | 21 | Citations (PDF) |
| 75 | Bioconjugation of Supramolecular Metallacages to Integrin Ligands for Targeted Delivery of Cisplatin | 3.9 | 54 | Citations (PDF) |
| 76 | Aquaporins in cancer development: opportunities for bioinorganic chemistry to contribute novel chemical probes and therapeutic agents | 2.6 | 66 | Citations (PDF) |
| 77 | On the Mechanism of Gold/NHC Compounds Binding to DNA G‐Quadruplexes: Combined Metadynamics and Biophysical Methods | 1.4 | 16 | Citations (PDF) |
| 78 | On the Mechanism of Gold/NHC Compounds Binding to DNA G‐Quadruplexes: Combined Metadynamics and Biophysical Methods | 14.4 | 69 | Citations (PDF) |
| 79 | Cyclometalated Complexes of Platinum and Gold with Biological Properties: State-of-the-Art and Future Perspectives | 2.6 | 65 | Citations (PDF) |
| 80 | Bioconjugation strategies to couple supramolecular exo-functionalized palladium cages to peptides for biomedical applications | 3.4 | 38 | Citations (PDF) |
| 81 | Nonconventional <i>trans</i>‐Platinum Complexes Functionalized with RDG Peptides: Chemical and Cytototoxicity Studies | 1.8 | 11 | Citations (PDF) |
| 82 | Mass spectrometry as a powerful tool to study therapeutic metallodrugs speciation mechanisms: Current frontiers and perspectives | 23.2 | 110 | Citations (PDF) |
| 83 | The mechanism of aquaporin inhibition by gold compounds elucidated by biophysical and computational methods | 3.4 | 54 | Citations (PDF) |
| 84 | Mechanistic Insights into Gold Organometallic Compounds and their Biomedical Applications | 0.8 | 38 | Citations (PDF) |
| 85 | A Potent Tartrate Resistant Acid Phosphatase Inhibitor to Study the Function of TRAP in Alveolar Macrophages | 3.5 | 23 | Citations (PDF) |
| 86 | A Multi‐Level Theoretical Study to Disclose the Binding Mechanisms of Gold(III)–Bipyridyl Compounds as Selective Aquaglyceroporin Inhibitors | 3.4 | 34 | Citations (PDF) |
| 87 | Exploring the C^N^C theme: Synthesis and biological properties of tridentate cyclometalated gold(III) complexes | 2.6 | 37 | Citations (PDF) |
| 88 | On the toxicity and transport mechanisms of cisplatin in kidney tissues in comparison to a gold-based cytotoxic agent | 2.6 | 25 | Citations (PDF) |
| 89 | Characterization of Hydrophilic Gold(I) N-Heterocyclic Carbene (NHC) Complexes as Potent TrxR Inhibitors Using Biochemical and Mass Spectrometric Approaches | 4.6 | 99 | Citations (PDF) |
| 90 | Functionalization of Ruthenium(II) Terpyridine Complexes with Cyclic RGD Peptides To Target Integrin Receptors in Cancer Cells | 1.8 | 27 | Citations (PDF) |
| 91 | Aquaporin modulators: a patent review (2010–2015) | 4.0 | 55 | Citations (PDF) |
| 92 | Mediterranean diet and multiple health outcomes: an umbrella review of meta-analyses of observational studies and randomised trials | 2.8 | 846 | Citations (PDF) |
| 93 | Anticancer Gold <i>N</i>‐Heterocyclic Carbene Complexes: A Comparative in vitro and ex vivo Study | 3.1 | 60 | Citations (PDF) |
| 94 | Nanoformulations of a Potent copper-based Aquaporin Inhibitor With Cytotoxic Effect Against Cancer Cells | 3.1 | 57 | Citations (PDF) |
| 95 | Potent in vitro antiproliferative properties for a triplatinum cluster toward triple negative breast cancer cells | 3.0 | 5 | Citations (PDF) |
| 96 | Evaluation of New Palladium Cages as Potential Delivery Systems for the Anticancer Drug Cisplatin | 3.4 | 140 | Citations (PDF) |
| 97 | Determinants for Tight and Selective Binding of a Medicinal Dicarbene Gold(I) Complex to a Telomeric DNA G‐Quadruplex: a Joint ESI MS and XRD Investigation | 1.4 | 47 | Citations (PDF) |
| 98 | Supramolecular exo-functionalized palladium cages: fluorescent properties and biological activity | 3.0 | 54 | Citations (PDF) |
| 99 | Toward anticancer gold-based compounds targeting PARP-1: a new case study | 4.4 | 13 | Citations (PDF) |
| 100 | Self‐Assembled Palladium and Platinum Coordination Cages: Photophysical Studies and Anticancer Activity | 1.8 | 52 | Citations (PDF) |
| 101 | Self-assembly of highly luminescent heteronuclear coordination cages | 3.0 | 52 | Citations (PDF) |
| 102 | Transition-metal norharmane compounds as possible cytotoxic agents: New insights based on a coordination chemistry perspective | 3.0 | 27 | Citations (PDF) |
| 103 | Ferrocenyl‐Coupled N‐Heterocyclic Carbene Complexes of Gold(I): A Successful Approach to Multinuclear Anticancer Drugs | 3.4 | 73 | Citations (PDF) |
| 104 | Determinants for Tight and Selective Binding of a Medicinal Dicarbene Gold(I) Complex to a Telomeric DNA G‐Quadruplex: a Joint ESI MS and XRD Investigation | 14.4 | 96 | Citations (PDF) |
| 105 | New Luminescent Polynuclear Metal Complexes with Anticancer Properties: Toward Structure–Activity Relationships | 4.6 | 75 | Citations (PDF) |
| 106 | Mass Spectrometry Uncovers Molecular Reactivities of Coordination and Organometallic Gold(III) Drug Candidates in Competitive Experiments That Correlate with Their Biological Effects | 4.6 | 56 | Citations (PDF) |
| 107 | Structure and biological activities of metal complexes of flumequine | 4.4 | 27 | Citations (PDF) |
| 108 | Exploring the gating mechanisms of aquaporin-3: new clues for the design of inhibitors? | 3.2 | 36 | Citations (PDF) |
| 109 | The inhibition of glycerol permeation through aquaglyceroporin-3 induced by mercury(II): A molecular dynamics study | 3.0 | 29 | Citations (PDF) |
| 110 | Exploring the potential of gold(<scp>iii</scp>) cyclometallated compounds as cytotoxic agents: variations on the C^N theme | 3.0 | 68 | Citations (PDF) |
| 111 | Improved Synthesis of <i>N</i>-Benzylaminoferrocene-Based Prodrugs and Evaluation of Their Toxicity and Antileukemic Activity | 5.6 | 82 | Citations (PDF) |
| 112 | Gold(I) NHC-based homo- and heterobimetallic complexes: synthesis, characterization and evaluation as potential anticancer agents | 2.5 | 106 | Citations (PDF) |
| 113 | Correlation between the Stereochemistry and Bioactivity in Octahedral Rhodium Prolinato Complexes | 4.6 | 17 | Citations (PDF) |
| 114 | Adjusting the DNA Interaction and Anticancer Activity of Pt(II) N-Heterocyclic Carbene Complexes by Steric Shielding of the Trans Leaving Group | 5.6 | 82 | Citations (PDF) |
| 115 | Reactivity of Cys4 Zinc Finger Domains with Gold(III) Complexes: Insights into the Formation of “Gold Fingers” | 4.6 | 41 | Citations (PDF) |
| 116 | Gold finger formation studied by high-resolution mass spectrometry and in silico methods | 3.4 | 44 | Citations (PDF) |
| 117 | Insights into the strong in-vitro anticancer effects for bis(triphenylphosphane)iminium compounds having perchlorate, tetrafluoridoborate and bis(chlorido)argentate anions | 3.0 | 14 | Citations (PDF) |
| 118 | Gold(I) N-heterocyclic carbene complexes with an “activable” ester moiety: Possible biological applications | 2.1 | 39 | Citations (PDF) |
| 119 | A Gold Coordination Compound as a Chemical Probe to Unravel Aquaporin‐7 Function | 2.6 | 43 | Citations (PDF) |
| 120 | Functional Inhibition of Aquaporin-3 With a Gold-Based Compound Induces Blockage of Cell Proliferation | 4.2 | 67 | Citations (PDF) |
| 121 | Cytotoxic Gold(I) N‐heterocyclic Carbene Complexes with Phosphane Ligands as Potent Enzyme Inhibitors | 3.1 | 83 | Citations (PDF) |
| 122 | Self-assembled M2L4 coordination cages: Synthesis and potential applications | 23.2 | 241 | Citations (PDF) |
| 123 | Nitrate as a probe of cytochrome c surface: Crystallographic identification of crucial “hot spots” for protein–protein recognition | 3.0 | 11 | Citations (PDF) |
| 124 | Caffeine-Based Gold(I) <i>N</i>-Heterocyclic Carbenes as Possible Anticancer Agents: Synthesis and Biological Properties | 4.6 | 230 | Citations (PDF) |
| 125 | Gold(<scp>i</scp>) compounds with lansoprazole-type ligands: synthesis, characterization and anticancer properties in vitro | 4.6 | 11 | Citations (PDF) |
| 126 | Luminescent iminophosphorane gold, palladium and platinum complexes as potential anticancer agents | 6.4 | 48 | Citations (PDF) |
| 127 | New Gold(I) Organometallic Compounds with Biological Activity in Cancer Cells | 1.8 | 87 | Citations (PDF) |
| 128 | Gold compounds as aquaporin inhibitors: new opportunities for therapy and imaging | 4.6 | 38 | Citations (PDF) |
| 129 | New heteronuclear gold(I)–platinum(II) complexes with cytotoxic properties: Are two metals better than one? | 3.0 | 70 | Citations (PDF) |
| 130 | Light-stable bis(norharmane)silver(I) compounds: Synthesis, characterization and antiproliferative effects in cancer cells | 3.0 | 29 | Citations (PDF) |
| 131 | Re(VII) and Tc(VII) trioxo complexes stabilized by tridentate ligands and their potential use as radiopharmaceuticals | 23.2 | 22 | Citations (PDF) |
| 132 | Cellular Transport Mechanisms of Cytotoxic Metallodrugs: An Overview beyond Cisplatin | 4.3 | 176 | Citations (PDF) |
| 133 | Aquaporin Inhibition by Gold(III) Compounds: New Insights | 3.1 | 85 | Citations (PDF) |
| 134 | A new target for gold(I) compounds: Glutathione-S-transferase inhibition by auranofin | 3.0 | 48 | Citations (PDF) |
| 135 | BODIPY–phosphane as a versatile tool for easy access to new metal-based theranostics | 3.0 | 57 | Citations (PDF) |
| 136 | Fluorescent silver(i) and gold(i)–N-heterocyclic carbene complexes with cytotoxic properties: mechanistic insights | 2.6 | 130 | Citations (PDF) |
| 137 | Emerging protein targets for metal-based pharmaceutical agents: An update | 23.2 | 138 | Citations (PDF) |
| 138 | Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs | 37.8 | 146 | Citations (PDF) |
| 139 | Potential Anticancer Heterometallic Fe–Au and Fe–Pd Agents: Initial Mechanistic Insights | 5.6 | 93 | Citations (PDF) |
| 140 | The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics | 3.0 | 38 | Citations (PDF) |
| 141 | The Formation of Oxytocin Dimers is Suppressed by the Zinc-Aspartate-Oxytocin Complex | 3.2 | 16 | Citations (PDF) |
| 142 | Influence of the π-coordinated arene on the anticancer activity of ruthenium(II) carbohydrate organometallic complexes | 3.6 | 27 | Citations (PDF) |
| 143 | Next-Generation Anticancer Metallodrugs | 3.0 | 203 | Citations (PDF) |
| 144 | Gold(I) Carbene Complexes Causing Thioredoxin <b>1</b> and Thioredoxin <b>2</b> Oxidation as Potential Anticancer Agents | 5.6 | 244 | Citations (PDF) |
| 145 | Reactivity and Biological Properties of a Series of Cytotoxic PtI<sub>2</sub>(amine)<sub>2</sub> Complexes, Either <i>cis</i> or <i>trans</i> Configured | 4.6 | 39 | Citations (PDF) |
| 146 | Cytotoxic gold compounds: synthesis, biological characterization and investigation of their inhibition properties of the zinc finger protein PARP-1 | 3.0 | 65 | Citations (PDF) |
| 147 | Interactions of anticancer Pt compounds with proteins: an overlooked topic in medicinal inorganic chemistry? | 7.1 | 183 | Citations (PDF) |
| 148 | Exploring the mechanisms of metalbased pharmacological agents via an integrated approach | 3.0 | 45 | Citations (PDF) |
| 149 | Targeting Aquaporin Function: Potent Inhibition of Aquaglyceroporin-3 by a Gold-Based Compound | 2.4 | 122 | Citations (PDF) |
| 150 | Thioredoxin reductase, an emerging target for anticancer metallodrugs. Enzyme inhibition by cytotoxic gold(iii) compounds studied with combined mass spectrometry and biochemical assays | 4.6 | 104 | Citations (PDF) |
| 151 | Conjugation of Organoruthenium(II) 3-(1<i>H</i>-Benzimidazol-2-yl)pyrazolo[3,4-<i>b</i>]pyridines and Indolo[3,2-<i>d</i>]benzazepines to Recombinant Human Serum Albumin: a Strategy To Enhance Cytotoxicity in Cancer Cells | 4.6 | 56 | Citations (PDF) |
| 152 | Multinuclear Cytotoxic Metallodrugs: Physicochemical Characterization and Biological Properties of Novel Heteronuclear Gold–Titanium Complexes | 4.6 | 85 | Citations (PDF) |
| 153 | Organometallic Ruthenium(II) Arene Compounds with Antiangiogenic Activity | 5.6 | 237 | Citations (PDF) |
| 154 | Metal-Based Inhibition of Poly(ADP-ribose) Polymerase − The Guardian Angel of DNA | 5.6 | 144 | Citations (PDF) |
| 155 | Thiolato gold(i) complexes containing water-soluble phosphane ligands: a characterization of their chemical and biological properties | 3.0 | 55 | Citations (PDF) |
| 156 | Mechanistic studies on two dinuclear organogold(iii) compounds showing appreciable antiproliferative properties and a high redox stability | 2.6 | 30 | Citations (PDF) |
| 157 | Structure, solution chemistry, antiproliferative actions and protein binding properties of non-conventional platinum(ii) compounds with sulfur and phosphorus donors | 3.0 | 29 | Citations (PDF) |
| 158 | Organometallic ruthenium-based antitumor compounds with novel modes of action | 2.1 | 344 | Citations (PDF) |
| 159 | Ruthenium(II) arene complexes with oligocationic triarylphosphine ligands: Synthesis, DNA interactions and in vitro properties | 2.1 | 18 | Citations (PDF) |
| 160 | Molecular Mechanisms and Proposed Targets for Selected Anticancer Gold Compounds | 3.0 | 190 | Citations (PDF) |
| 161 | Trace Copper(II) or Zinc(II) Ions Drastically Modify the Aggregation Behavior of Amyloid-β1–42: An AFM Study | 2.6 | 86 | Citations (PDF) |
| 162 | Anticancer Therapeutics That Target Selenoenzymes: Synthesis, Characterization, in vitro Cytotoxicity, and Thioredoxin Reductase Inhibition of a Series of Gold(I) Complexes Containing Hydrophilic Phosphine Ligands | 3.1 | 121 | Citations (PDF) |
| 163 | Proteins as Possible Targets for Cytotoxic <i>trans</i>‐Platinum(II) Complexes with Aliphatic Amine Ligands: Further Exceptions to the DNA Paradigm | 3.1 | 25 | Citations (PDF) |
| 164 | Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies | 13.8 | 476 | Citations (PDF) |
| 165 | Trans–cis–cis-[RuCl2(DMSO)2(2-amino-5-methyl-thiazole)2], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B | 3.0 | 16 | Citations (PDF) |
| 166 | Anticancer activity of new organo-ruthenium, rhodium and iridium complexes containing the 2-(pyridine-2-yl)thiazole N,N-chelating ligand | 2.1 | 125 | Citations (PDF) |
| 167 | Reactivity of anticancer metallodrugs with serum proteins: new insights from size exclusion chromatography-ICP-MS and ESI-MS | 3.1 | 98 | Citations (PDF) |
| 168 | Antiproliferative Activity of Gold(I) Alkyne Complexes Containing Water-Soluble Phosphane Ligands | 2.9 | 102 | Citations (PDF) |
| 169 | Cytotoxic Profile and Peculiar Reactivity with Biomolecules of a Novel “Rule-Breaker” Iodidoplatinum(II) Complex | 3.4 | 33 | Citations (PDF) |
| 170 | Synthesis, characterisation and biological properties of gold(iii) compounds with modified bipyridine and bipyridylamine ligands | 3.0 | 84 | Citations (PDF) |
| 171 | Rationalization of the inhibition activity of structurally related organometallic compounds against the drug target cathepsin B by DFT | 3.0 | 85 | Citations (PDF) |
| 172 | The X‐ray Structure of the Adduct between NAMI‐A and Carbonic Anhydrase Provides Insights into the Reactivity of this Metallodrug with Proteins | 3.1 | 44 | Citations (PDF) |
| 173 | [Au<sub>2</sub>(phen<sup>2Me</sup>)<sub>2</sub>(μ<b>-</b>O)<sub>2</sub>](PF<sub>6</sub>)<sub>2</sub>, a Novel Dinuclear Gold(III) Complex Showing Excellent Antiproliferative Properties | 3.4 | 83 | Citations (PDF) |
| 174 | Development of Bimetallic Titanocene−Ruthenium−Arene Complexes As Anticancer Agents: Relationships between Structural and Biological Properties | 5.6 | 97 | Citations (PDF) |
| 175 | Solution Behaviour and Biomolecular Interactions of Two Cytotoxic <i>trans</i>‐Platinum(II) Complexes Bearing Aliphatic Amine Ligands | 3.4 | 23 | Citations (PDF) |
| 176 | Exploring metallodrug–protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound | 2.5 | 105 | Citations (PDF) |
| 177 | Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study | 2.5 | 128 | Citations (PDF) |
| 178 | Outstanding plasmodicidal properties within a small panel of metallic compounds: Hints for the development of new metal-based antimalarials | 3.0 | 31 | Citations (PDF) |
| 179 | Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs | 23.2 | 571 | Citations (PDF) |
| 180 | Reactivity of an antimetastatic organometallic ruthenium compound with metallothionein-2: relevance to the mechanism of action | 2.6 | 64 | Citations (PDF) |
| 181 | Excellent correlation between cathepsin B inhibition and cytotoxicity for a series of palladacycles | 3.0 | 68 | Citations (PDF) |
| 182 | Clioquinol Decreases Amyloid-β Burden and Reduces Working Memory Impairment in a Transgenic Mouse Model of Alzheimer's Disease | 2.6 | 121 | Citations (PDF) |
| 183 | Peculiar mechanistic and structural features of the carboplatin–cytochrome c system revealed by ESI-MS analysis | 2.5 | 35 | Citations (PDF) |
| 184 | The Influence of Auranofin, a Clinically Established Antiarthritic Gold Drug, on Bone Metabolism: Analysis of Its Effects on Human Multipotent Adipose‐Derived Stem Cells, Taken as a Model | 2.3 | 12 | Citations (PDF) |
| 185 | Gold(III) compounds as anticancer agents: Relevance of gold–protein interactions for their mechanism of action | 3.0 | 264 | Citations (PDF) |
| 186 | Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: New insights from X-ray diffraction and mass spectrometry studies | 3.0 | 84 | Citations (PDF) |
| 187 | Stability of an organometallic ruthenium–ubiquitin adduct in the presence of glutathione: Relevance to antitumour activity | 3.0 | 63 | Citations (PDF) |
| 188 | New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects <i>in vitro</i>: Mechanistic and pharmacological implications | 2.7 | 161 | Citations (PDF) |
| 189 | Emerging Protein Targets for Anticancer Metallodrugs: Inhibition of Thioredoxin Reductase and Cathepsin B by Antitumor Ruthenium(II)−Arene Compounds | 5.6 | 269 | Citations (PDF) |
| 190 | Structural Characterization, Solution Studies, and DFT Calculations on a Series of Binuclear Gold(III) Oxo Complexes: Relationships to Biological Properties | 4.6 | 105 | Citations (PDF) |
| 191 | Potential pathogenic role of β-amyloid1–42–aluminum complex in Alzheimer's disease | 2.7 | 79 | Citations (PDF) |
| 192 | A multi-technique approach to predicting the molecular structure of cuprizone in the gas phase and in the crystalline state | 2.4 | 2 | Citations (PDF) |
| 193 | Exploiting Soft and Hard X-Ray Absorption Spectroscopy to Characterize Metallodrug/Protein Interactions: the Binding of [<i>trans</i>-RuCl<sub>4</sub>(Im)(dimethylsulfoxide)][ImH] (Im = imidazole) to Bovine Serum Albumin | 4.6 | 51 | Citations (PDF) |
| 194 | Antiplasmodial Effects of a few Selected Natural Flavonoids and their Modulation of Artemisinin Activity | 0.6 | 9 | Citations (PDF) |
| 195 | Mass spectrometric analysis of ubiquitin–platinum interactions of leading anticancer drugs: MALDI versus ESI | 3.1 | 93 | Citations (PDF) |
| 196 | Insights into the Molecular Mechanisms of Protein Platination from a Case Study: The Reaction of Anticancer Platinum(II) Iminoethers with Horse Heart Cytochrome c | 2.4 | 52 | Citations (PDF) |
| 197 | Antimalarial properties of green tea | 2.1 | 68 | Citations (PDF) |
| 198 | ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme | 3.4 | 142 | Citations (PDF) |
| 199 | Unravelling the chemical nature of copper cuprizone | 3.0 | 57 | Citations (PDF) |
| 200 | New Copper(II)/Cyclic Tetrapeptide System That Easily Oxidizes to Copper(III) under Atmospheric Oxygen | 4.6 | 29 | Citations (PDF) |
| 201 | fac-{Ru(CO)3}2+-Core Complexes and Design of Metal-Based Drugs. Synthesis, Structure, and Reactivity of Ru−Thiazole Derivative with Serum Proteins and Absorption−Release Studies with Acryloyl and Silica Hydrogels as Carriers in Physiological Media | 4.6 | 38 | Citations (PDF) |
| 202 | Activity of Rat Cytosolic Thioredoxin Reductase Is Strongly Decreased bytrans-[Bis(2-amino-5- methylthiazole)tetrachlororuthenate(III)]: First Report of Relevant Thioredoxin Reductase Inhibition for a Ruthenium Compound | 5.6 | 53 | Citations (PDF) |
| 203 | ESI–MS Characterisation of Protein Adducts of Anticancer Ruthenium(II)-Arene PTA (RAPTA) Complexes | 3.1 | 88 | Citations (PDF) |
| 204 | DOTAP/DOPE and DC-Chol/DOPE lipoplexes for gene delivery studied by circular dichroism and other biophysical techniques | 2.1 | 38 | Citations (PDF) |
| 205 | Gold(III) compounds as anticancer drugs | 0.8 | 137 | Citations (PDF) |
| 206 | Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c | 2.5 | 49 | Citations (PDF) |
| 207 | Structural and Solution Chemistry, Antiproliferative Effects, and DNA and Protein Binding Properties of a Series of Dinuclear Gold(III) Compounds with Bipyridyl Ligands | 5.6 | 191 | Citations (PDF) |
| 208 | The reaction of artemisinins with hemoglobin: A unified picture | 2.6 | 66 | Citations (PDF) |
| 209 | Structural Investigation of Cisplatin–Protein Interactions: Selective Platination of His19 in a Cuprozinc Superoxide Dismutase | 14.4 | 107 | Citations (PDF) |
| 210 | Exploring Metallodrug–Protein Interactions by ESI Mass Spectrometry: The Reaction of Anticancer Platinum Drugs with Horse Heart Cytochrome c | 3.1 | 92 | Citations (PDF) |
| 211 | Structural Investigation of Cisplatin–Protein Interactions: Selective Platination of His19 in a Cuprozinc Superoxide Dismutase | 1.4 | 5 | Citations (PDF) |
| 212 | Carbonic anhydrase inhibitors: X-ray crystal structure of a benzenesulfonamide strong CA II and CA IX inhibitor bearing a pentafluorophenylaminothioureido tail in complex with isozyme II | 2.1 | 41 | Citations (PDF) |
| 213 | Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies | 2.1 | 186 | Citations (PDF) |
| 214 | Carbonic anhydrase inhibitors: Design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowering activity in a rabbit model of glaucoma | 2.1 | 28 | Citations (PDF) |
| 215 | Carbonic anhydrase inhibitors: Inhibition of the tumor-associated isozymes IX and XII with polyfluorinated aromatic/heterocyclic sulfonamides | 5.2 | 21 | Citations (PDF) |
| 216 | Carbonic Anhydrase Inhibitors: Synthesis and Inhibition of Cytosolic/Membrane-Associated Carbonic Anhydrase Isozymes I, II, and IX with Sulfonamides Incorporating Hydrazino Moieties | 5.6 | 72 | Citations (PDF) |
| 217 | Characterization of CA XIII, a Novel Member of the Carbonic Anhydrase Isozyme Family | 2.2 | 227 | Citations (PDF) |
| 218 | COX-2 Selective Inhibitors, Carbonic Anhydrase Inhibition and Anticancer Properties of Sulfonamides Belonging to This Class of Pharmacological Agents | 2.6 | 138 | Citations (PDF) |
| 219 | Designing of Novel Carbonic Anhydrase Inhibitors and Activators | 1.2 | 141 | Citations (PDF) |
| 220 | New Developments on Thromboxane and Prostacyclin Modulators Part I: Thromboxane Modulators | 2.6 | 78 | Citations (PDF) |
| 221 | Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX | 2.1 | 261 | Citations (PDF) |
| 222 | Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase | 2.1 | 149 | Citations (PDF) |
| 223 | Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides | 2.1 | 86 | Citations (PDF) |
| 224 | Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-α-d-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits | 2.1 | 70 | Citations (PDF) |
| 225 | Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride | 2.1 | 73 | Citations (PDF) |
| 226 | Carbonic anhydrase inhibitors: The first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX | 2.1 | 152 | Citations (PDF) |
| 227 | Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with a topically acting antiglaucoma sulfonamide | 2.1 | 49 | Citations (PDF) |
| 228 | Carbonic anhydrase inhibitors. Inhibition of cytosolic isozyme XIII with aromatic and heterocyclic sulfonamides: a novel target for the drug design | 2.1 | 38 | Citations (PDF) |
| 229 | Carbonic Anhydrase Inhibitors: Aliphatic N-phosphorylated Sulfamates--A Novel Zinc-anchoring Group Leading to Nanomolar Inhibitors | 5.2 | 11 | Citations (PDF) |
| 230 | Unexpected Nanomolar Inhibition of Carbonic Anhydrase by COX-2-Selective Celecoxib: New Pharmacological Opportunities Due to Related Binding Site Recognition | 5.6 | 443 | Citations (PDF) |
| 231 | Carbonic Anhydrase Inhibitors: Synthesis and Topical Intraocular Pressure Lowering Effects of Fluorine-Containing Inhibitors Devoid of Enhanced Reactivity | 5.6 | 39 | Citations (PDF) |
| 232 | Carbonic Anhydrase Inhibitors: The First On-Resin Screening of a 4-Sulfamoylphenylthiourea Library | 5.6 | 48 | Citations (PDF) |
| 233 | Hypoxia activates the capacity of tumor‐associated carbonic anhydrase IX to acidify extracellular pH | 2.7 | 647 | Citations (PDF) |
| 234 | Carbonic anhydrase inhibitors | 13.8 | 1,188 | Citations (PDF) |
| 235 | Protease inhibitors of the sulfonamide type: Anticancer, antiinflammatory, and antiviral agents | 13.8 | 428 | Citations (PDF) |
| 236 | Carbonic anhydrase inhibitors | 2.1 | 85 | Citations (PDF) |
| 237 | Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV | 2.1 | 228 | Citations (PDF) |
| 238 | Carbonic anhydrase activators. The selective serotonin reuptake inhibitors fluoxetine, sertraline and citalopram are strong activators of isozymes I and II | 2.1 | 31 | Citations (PDF) |
| 239 | Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with a bis-sulfonamide—two heads are better than one? | 2.1 | 36 | Citations (PDF) |
| 240 | Carbonic anhydrase inhibitors: Topically acting antiglaucoma sulfonamides incorporating esters and amides of 3- and 4-carboxybenzolamide | 2.1 | 34 | Citations (PDF) |
| 241 | Predicting bone mineral density of postmenopausal healthy and cirrhotic Italian women using anthropometric variables | 2.4 | 7 | Citations (PDF) |
| 242 | Carbonic Anhydrase Inhibitors: Inhibition of Transmembrane, Tumor-Associated Isozyme IX, and Cytosolic Isozymes I and II with Aliphatic Sulfamates | 5.6 | 79 | Citations (PDF) |
| 243 | Carbonic Anhydrase Inhibitors. Inhibition of Cytosolic Isozymes I and II and Transmembrane, Tumor-Associated Isozyme IX with Sulfamates Including EMATE Also Acting as Steroid Sulfatase Inhibitors | 5.6 | 141 | Citations (PDF) |
| 244 | Carbonic Anhydrase Inhibitors: X-ray Crystallographic Structure of the Adduct of Human Isozyme II with the Perfluorobenzoyl Analogue of Methazolamide. Implications for the Drug Design of Fluorinated Inhibitors | 5.2 | 50 | Citations (PDF) |
| 245 | Targeting Cysteine Residues of Biomolecules: New Approaches for the Design of Antiviral and Anticancer Drugs | 2.6 | 56 | Citations (PDF) |
| 246 | Sulfonamides and Sulfonylated Derivatives as Anticancer Agents | 2.5 | 276 | Citations (PDF) |
| 247 | Carbonic Anhydrase Inhibitors With Strong Topical Antiglaucoma Properties Incorporating a 4-(2-amino-pyrimidin-4-yl-amino)-benzenesulfonamide Scaffold | 5.2 | 15 | Citations (PDF) |
| 248 | Carbonic Anhydrase Inhibitors: Synthesis of Water Soluble Sulfonamides Incorporating a 4-sulfamoylphenylmethylthiourea Scaffold, with Potent Intraocular Pressure Lowering Properties | 5.2 | 35 | Citations (PDF) |
| 249 | Cysteine-modifying agents: a possible approach for effective anticancer and antiviral drugs. | 8.8 | 34 | Citations (PDF) |
| 250 | Cyclodextrin Complexes of Sulfonamide Carbonic Anhydrase IOnhibitors As Long‐lasting Topically Acting Antiglaucoma Agents | 3.2 | 17 | Citations (PDF) |
| 251 | Carbonic Anhydrase Inhibitors: Synthesis and Inhibition Against Isozymes I, II and IV of Topically Acting Antiglaucoma Sulfonamides Incorporating<i>cis</i>-5-Norbornene-<i>endo</i>-3-Carboxy-2-Carboxamido Moieties | 0.5 | 8 | Citations (PDF) |
| 252 | Interactions of two cytotoxic organotin(IV) compounds with calf thymus DNA | 3.0 | 52 | Citations (PDF) |
| 253 | Carbonic anhydrase inhibitors: 4-sulfamoyl-benzenecarboxamides and 4-chloro-3-sulfamoyl-benzenecarboxamides with strong topical antiglaucoma properties | 2.1 | 62 | Citations (PDF) |
| 254 | Synthesis, molecular structure and solution chemistry of the iridium(III) complex imidazolium [trans(bisimidazole)tetrachloro iridate(III)] (IRIM) | 2.8 | 40 | Citations (PDF) |
| 255 | Carbonic anhydrase inhibitors: sulfonamides incorporating furan-, thiophene- and pyrrole-carboxamido groups possess strong topical intraocular pressure lowering properties as aqueous suspensions | 2.6 | 68 | Citations (PDF) |
| 256 | Effects of two representative antitumor ruthenium(III) complexes on thermal denaturation profiles of DNA | 2.8 | 21 | Citations (PDF) |
| 257 | DNA as a Possible Target for Antitumor Ruthenium(III) Complexes | 2.9 | 117 | Citations (PDF) |
| 258 | Formation of Supramolecular Structures between DNA and Starburst Dendrimers Studied by EPR, CD, UV, and Melting Profiles | 5.0 | 125 | Citations (PDF) |
| 259 | Carbonic Anhydrase Inhibitors: Water-Soluble 4-Sulfamoylphenylthioureas as Topical Intraocular Pressure-Lowering Agents with Long-Lasting Effects | 5.6 | 145 | Citations (PDF) |
